Five-year results of thoracic endovascular aortic repair with the Zenith TX2  by Matsumura, Jon S. et al.
CLINICAL RESEARCH STUDIESFrom
R
pi
In
th
This
Auth
di
In
fo
ip
ed
C
Ad
em
Clin
ct
Rep
60
The
to
m
0741
Cop
El
httpFive-year results of thoracic endovascular aortic
repair with the Zenith TX2
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Shraddha Mehta, PhD,e Lars G. Svensson, MD,f and Randy D. Moore, MD,g for the Zenith TX2 Clinical
Trial Investigators, Madison, Wisc; Milan, Italy; Boston, Mass; Palo Alto, Calif; West Lafayette, Ind; Cleveland,
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Background: This trial evaluated thoracic endovascular aortic repair (TEVAR) compared with open surgical repair of
descending thoracic aortic aneurysms and large ulcers at 42 international sites. Whereas several studies demonstrate early
safety and utility advantages with TEVAR, longer follow-up is important because of concerns about durability of TEVAR.
Methods: This prospective, nonrandomized study enrolled 160 TEVAR patients treated with the Cook Zenith TX2 and 70
open surgical repair patients.
Results: Although follow-up was limited, 5-year mortality rate was similar at 37% for both groups. Aneurysm-related
mortality rate was 5.9% with TEVAR compared with 12% with open surgical repair (P [ .11). There were no rup-
tures of the treated aneurysms in either group or open conversions in the TEVAR group. Predeﬁned severe morbidity
occurred at a signiﬁcantly lower rate in TEVAR (21%) compared with open surgical repair (39%; P < .001). Aneurysm
growth was seen by core laboratory in 5.9% of patients and endoleak in 5.7% of patients. Secondary intervention rates
were similar between TEVAR (8%) and open surgical repair (12%; P [ .49) patients.
Conclusions: Five-year results indicate similar all-cause mortality and aneurysm-related mortality with TEVAR compared
with open repair. There was a persistent reduction of severe complications with TEVAR. Reinterventions occurred with
similar frequency. TEVAR with the TX2 is a safe and effective alternative to open surgical repair for the treatment of
anatomically suitable descending thoracic aortic aneurysms and ulcers. (J Vasc Surg 2014;60:1-10.)Thoracic endovascular aortic repair (TEVAR) is an
example of less invasive approaches to vascular disease
that has great potential to alter treatment paradigms.
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://dx.doi.org/10.1016/j.jvs.2014.01.043have been classically treated with risk factor control and
observation until growth to a sufﬁcient size that the risk
of rupture justiﬁes the risks of a major thoracic operation.
Whereas these aortic diseases have been treated for many
years with TEVAR, there are limited long-term data to
address concerns about late failure rates with the newer
technology.1-7 There are speciﬁc concerns that late failure
modes may mitigate striking early beneﬁts. We conducted
a large, multicenter trial with regulatory audit and detailed
comparisons of 5-year outcomes between open surgical
repair and TEVAR in the treatment of degenerative aneu-
rysms and ulcers of the descending thoracic aorta.
METHODS
Trial design. The Zenith TX2 pivotal study was a non-
randomized, controlled, multicenter, international trial
designed to evaluate the safety and effectiveness of the
Zenith TX2 TAA Endovascular Graft (William Cook
Europe, ApS, Bjaeverskov, Denmark) in patients with
descending TAAs$5 cm, rapid growth$5 mm/y, or ulcer
$10 mm in depth and 20 mm in diameter. A detailed
description of the TEVAR device, its deployment system,
endovascular and open surgical repair techniques, and trial
design with patient inclusion and exclusion criteria has
been previously published.8 Some facets of the trial design
deserve repetition. Whereas a randomized design was1
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marked differences in short-term results, and the in-
vestigators did not have sufﬁcient equipoise to justify
randomization of patients. Few open surgical repairs were
being conducted during the course of the study, limiting
our ability to enroll prospective surgical control patients and
thereby requiring enrollment of consecutive retrospective
controls. Because of these design issues, we established
anatomic criteria to enroll comparable patients in both co-
horts. Per protocol, TEVAR patients were required to have
a 3-cm proximal and distal neck length according to the site
measurements. Patients undergoing open surgical repair
needed to have planned sutured anastomoses between the
left common carotid artery and celiac trunk artery. Patients
with type I thoracoabdominal aneurysms were eligible for the
study if the placement of endograft fabric was planned to be
above the visceral vessels or if there was no planned mesen-
teric revascularization with open repair.
From 2002 to 2006, the pivotal study enrolled 160 pa-
tients for endovascular repair and 70 patients for surgical
repair at 42 investigative sites in the United States, Canada,
Europe, and Australia. Results through 1 year and 2 years
have been published earlier.1,2 All patients in this trial
received treatment with the available technology at the
time. Speciﬁcally, this was before introduction of modiﬁca-
tions of the deployment system, such as the Pro-Form,
which allows more parallel apposition of the proximal seal-
ing stent in the inner curve of the aortic arch and more
trackable and ﬂexible delivery system introducers and
sheaths. This report presents the ﬁnal data set through 5-
year follow-up, reﬂecting the data as of February 23, 2012.
The study was performed according to the Declaration
of Helsinki II. Ethical approval was obtained from the rele-
vant institutional review board or ethics committee at each
institution. All subjects signed an informed consent.
Patient follow-up. Patients in the open surgical con-
trol group underwent clinical evaluation before discharge
or at 1 month and then at 12 months and yearly thereafter
up to 5 years. Of 70 surgical patients, 24 could not be
observed beyond 1 year because the institutional review
board/ethics committee-approved follow-up at their
respective investigative sites was limited to 12 months. For
endovascular patients, follow-up computed tomography
(CT) scans, device radiographs, physical examinations, and
laboratory studies were performed before discharge and at
1, 6, and 12 months and yearly thereafter up to 5 years. All
CT images were analyzed by an independent core labora-
tory. Per protocol, core laboratory ﬁndings were conﬁrmed
by the independent clinical events committee (CEC).
Unless otherwise indicated, imaging data reported in this
manuscript reﬂect the results from core laboratory analysis.
Deﬁnitions. TAA-related mortality was deﬁned as all
deaths occurring within 30 days of implant procedure, sec-
ondary intervention, or conversion regardless of cause and
those adjudicated as related to TAA repair by an indepen-
dent CEC. The CEC reviewed all patient deaths and iden-
tiﬁed TAA-related deaths in cases in which the procedure,
aneurysm disease progression, or sequence of eventsbeginning within 30 days of the procedure may have
contributed to the eventual death. Severe morbid events
comprise 13 predeﬁned morbid events as previously re-
ported; they represent a subset from 57 predeﬁned morbid
events recorded in the study and are major complications
commonly used by clinicians in comparing TEVAR and
open aortic repair.8 For example, the severe morbid events
include paraplegia, return to operating room for bleeding,
and permanent dialysis; morbid events also include tran-
sient weakness, postprocedure transfusion, and more
than 30% elevation of serum creatinine concentration.
Endoleaks were classiﬁed as type I through IV according to
the standard deﬁnitions.9 An increase in aneurysm or ulcer
size was deﬁned as a >5 mm increase in the major diameter
of the aneurysm sac or the depth of the ulcer at follow-up
time points compared with the predischarge CT scan.
Radiographic device migration, which was identiﬁed by the
imaging core laboratory and veriﬁed by the CEC, was
deﬁned as caudal or cranial movement of the proximal or
distal components of the TX2 device >10 mm relative to
anatomic landmarks identiﬁed on the ﬁrst technically
adequate postoperative CT scan.9 Clinically signiﬁcant
migration was deﬁned as migration resulting in the need
for secondary intervention. Device integrity was assessed
from follow-up CT scans and radiographic images by the
core laboratory. Incidences of stent fracture and barb
separation were conﬁrmed by the CEC.
Data analysis. Data were managed by a centralized
data coordinating center, MED Institute, Inc. Statistical
analyses were performed with SAS for Windows (release
9.3 or higher; SAS Institute, Cary, NC). Continuous vari-
ables were reported as means and standard deviations un-
less otherwise indicated, and P values were calculated
with standard t-tests. Dichotomous and other categorical
variables were reported as percentages. The Kaplan-Meier
method was used to estimate freedom from all-cause
mortality, aneurysm-related mortality, severe morbid
events, morbid events, and secondary interventions.RESULTS
Patients and follow-up availability. The Zenith TX2
pivotal study enrolled 160 endovascular patients and 70
open surgical control patients. The details of these two pa-
tient groups were published previously.1 Twenty-six sites
enrolled at least one open surgical patient, including one
site that enrolled 14. Poolability analysis for open surgical
patients indicated homogeneity of mortality results from
multiple sites. In the endovascular group, 158 of 160 pa-
tients were successfully implanted with the TEVAR device.
Two patients did not undergo TEVAR because of inability
to insert or to advance the introducer system, completed
30-day follow-up, and have no further follow-up.1 Another
32 TEVAR subjects and 28 control subjects were lost to
follow-up, withdrew, or had limited consent to follow-up.
At 5 years, among patients eligible for follow-up, 93% (68
of 73) of the endovascular patients and 48% (12 of 25) of
the surgical patients received clinical examinations, and
Fig 1. Subject follow-up availability at 5 years. CT, Computed
tomography; IRB/EC, institutional review board/ethics commit-
tee; LTF, lost to follow-up; n/a, not applicable; TEVAR, thoracic
endovascular aortic repair.
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scans (Fig 1).
Mortality. During follow-up through 5 years, 51
deaths occurred in the endovascular group and 17 deaths
occurred in the open surgical control group. The survival
estimate from all-cause mortality was 62.9% for the endo-
vascular treatment group and 62.8% for the open surgical
control group at 5 years (1825 days), with no signiﬁcant
difference in the survival curves between the two groups
(Fig 2; log-rank: P ¼ .88). Causes for all deaths are sum-
marized in Table I.
The Kaplan-Meier analysis indicated a trend that was
not statistically signiﬁcant (log-rank, P ¼ .11) toward
higher survival estimates from TAA-related mortality in
the endovascular group (Fig 3). The survival estimate
from TAA-related mortality was 94.1% for the endovascu-
lar treatment group and 88.3% for the control group
at 5 years. A summary of deaths included in the
TAA-related mortality analysis is provided in Table II.
Ascertainment of cause of death is often uncertain, and
for nine deaths in the study (six in the endovascular
group, three in the surgical group), the independent
CEC could not determine whether they were related to
aneurysm treatment (ie, indeterminate). In most of these
cases, the deaths were reported by the family or the Social
Security Death Index. To avoid missing some aneurysm-
related deaths, a sensitivity analysis was performed to
include these indeterminate deaths as TAA related in
the Kaplan-Meier analysis. A similar trend of higher sur-
vival from TAA-related mortality was observed for the
endovascular group (88.7% at 5 years) than for the surgi-
cal group (76.7% at 5 years), again without statistical
signiﬁcance (log-rank, P ¼ .07). In summary, there was
no difference in all-cause or aneurysm-related mortality
at 5 years.
Rupture and conversion. There were no ruptures of
the treated aneurysm in either group or conversions to
open repair in the TEVAR group.
Morbidity. The early results of the TX2 study demon-
strated a striking reduction of prespeciﬁed severe morbidity
for endovascular patients at 30 days.2 Kaplan-Meier anal-
ysis of freedom from severe morbid events indicates thatthis beneﬁt was maintained through 5 years of follow-up
(Fig 4; log-rank test, P < .001). The Kaplan-Meier esti-
mates of freedom from severe morbid events for endovas-
cular and open surgical control patients were 87.3% vs
64.3% at 1 year and 79.1% vs 61.2% at 5 years. Overall, 30
endovascular patients and 26 surgical patients experienced
at least one severe morbid event within 5 years. Among
these patients, the average number of severe morbid events
per patient was 1.9 6 1.3 (range, 1-5) in the endovascular
group and 2.7 6 2.4 (range, 1-13) in the control group
(P ¼ .15).
In addition, the Kaplan-Meier analysis of predeﬁned
morbid events by category shows that endovascular pa-
tients had similar rates of renal, gastrointestinal, wound,
and neurologic morbidity compared with the open surgical
control patients. However, endovascular patients had
signiﬁcantly lower cardiovascular morbidity (log-rank,
P ¼ .003), pulmonary morbidity (log-rank, P < .001),
and vascular morbidity (log-rank, P ¼ .01) during the
5-year follow-up. Furthermore, although neurologic
morbidity (comprising stroke, transient ischemic attack/
reversible ischemic neurologic deﬁcit, carotid artery embo-
lization/occlusion, paraparesis, and paraplegia) was similar
between the two groups, an examination of individual
neurologic events showed that the endovascular patients
had a signiﬁcantly lower occurrence of strokes (log-rank,
P < .05) and paraplegia (log-rank, P < .05). There was
only one late paraparesis that occurred in the ﬁfth year in
a TEVAR patient; a spinal drain was placed and the patient
discharged to home after rehabilitation and ambulating
without assistance 8 months later.
Endoleaks. Results of endoleaks are summarized in
Table III. The occurrence of type I or III endoleak was
low: only nine patients were found to have a type I or III
endoleak during 5 years of follow-up. There were no
proximal type I endoleaks in the ﬁrst 3 years; only two
patients at the 4-year and 5-year follow-up had a proximal
type I endoleak. These two patients did not experience
aneurysm growth or secondary interventions. Both patients
had an inverted funnel-shaped proximal neck on pre-
procedural imaging and an insufﬁciently oversized proximal
component placement on retrospective imaging review,
and both had experienced a device migration during earlier
follow-up (1-year and 2-year, respectively). Distal type I
endoleak was observed in three patients, and two have
undergone reintervention. In both these patients, a funnel-
shaped distal neck and insufﬁcient device oversizing at the
distal end were observed. Type III endoleak was detected
in four patients; three resolved spontaneously, and the
fourth patient experienced component separation and un-
derwent a reintervention that successfully bridged the
separated components. None of the patients with a type II
endoleak underwent secondary intervention.
Change in aneurysm or ulcer size. The aneurysm sac
size or ulcer depth decreased or remained stable in more
than 90% of patients through 5 years (Table IV). A total
of 14 patients were found to have an increase >5 mm in
their pathology during follow-up. Six of these experienced
Table I. Causes of deaths included in the all-cause
mortality analysis
Cause of death
(reported by site)
Endovascular,
No. (% of
all deaths)
Surgical,
No. (% of
all deaths)
Cancer 3 (6) 1 (6)
Cardiac 9 (17) 5 (29)
Organ failure 6 (12) 0
Paralysis 0 2 (12)
Pneumonia 3 (6) 0
Respiratory failure 4 (8) 1 (6)
Rupture (nonstudy aneurysm) 2 (4)a 0
Sepsis 8 (15) 1 (6)
Shock 0 1 (6)b
Stroke 7 (13) 3 (18)
Surgical complications 1 (2) 0
Unknown 9 (17) 3 (18)
Total 52 17
aTwo patients died of rupture of a nonstudy aneurysm: one patient had a
rupture of a femoral artery aneurysm (a preexisting condition), and one
patient had a rupture of a known enlarging distal thoracoabdominal aneu-
rysm unrelated to the initial endovascular repair with the TEVAR device and
for which the patient refused treatment.
bThis patient exhibited sudden signs of shock, including cold and
clammy skin, decreased blood pressure, and decreased level of con-
sciousness. It was suspected that the patient experienced aneurysm
leaking or rupture.
Fig 2. Kaplan-Meier (K-M) estimate of survival for the endovascular group and surgical control group. There is no
difference in survival by univariate analysis (log-rank, P ¼ .88). The vertical lines represent 95% conﬁdence intervals.
The standard error (SE) is less than 10% through 5 years. TEVAR, Thoracic endovascular aortic repair.
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depth (to below the extent of 5 mm increase) at later
follow-up. Five patients underwent reintervention: one
died after two reinterventions for continued growth
without detectable endoleak, and the other four had sta-
bilized (ie, no further growth) or decreased aneurysm size
after the reinterventions. Of the remaining three patients,
one expired with a non-TAA-related death (pancreatitis)
without further follow-up, and two who experienced late
growth (one at 4 years and 5 years and one at 5 years) did
not have endoleaks or require secondary intervention at the
5-year follow-up.
Migration. CEC-conﬁrmed radiographic graft migra-
tion >10 mm occurred in 12 patients. Caudal migration of
the proximal component was observed in nine patients, and
among them, one patient also had a concomitant cranial
migration of the distal component. In addition, two pa-
tients had a cranial migration of the distal end of the stent
graft, and one patient had caudal migration of the proximal
end and cranial migration of the distal end of the same
stent graft. Retrospective imaging review revealed that all
12 patients had inadequate aortic neck anatomy at the loca-
tion where the device was deployed: 11 patients had an
inverted funnel-shaped proximal neck, 10 of whom also
had a funnel-shaped distal neck, and one patient had
Fig 3. Kaplan-Meier estimate of freedom from thoracic aortic aneurysm (TAA)-related deaths for the endovascular
treatment group and open surgical control group (log-rank, P ¼ .11). The vertical lines represent 95% conﬁdence
intervals. TEVAR, Thoracic endovascular aortic repair; SE, standard error.
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ential thrombus in the proximal or distal neck was also seen
in ﬁve patients. In addition, insufﬁcient stent graft over-
sizing at the location of actual graft placement was
observed in all but one patient (less than 10% oversizing,
which was the minimum labeled oversizing).
Among the 12 cases of conﬁrmed device migration,
two cases were clinically signiﬁcant and required secondary
intervention. One patient underwent a secondary interven-
tion, and the aneurysm size had decreased to the level of
baseline size at the 60-month follow-up. In the second pa-
tient, a cranial migration of the distal end of the stent graft
required a secondary intervention (placement of a distal
main body extension), which successfully resolved an asso-
ciated distal type I endoleak.3
Device integrity. Twenty-one patients had device
integrity issues on the basis of core laboratory analysis
and conﬁrmed by the CEC (for barb separation and stent
fractures). One patient had a distal bare stent strut entan-
glement from predischarge through 12 months,1 which
was not associated with migration, endoleak, aneurysm
growth, or the need for secondary intervention before the
patient was lost to follow-up. There were four cases of stent
fractures (single fracture in three cases and two fractures of
a distal stent in one case); none resulted in type I or III
endoleak or migration of the affected device component,and none required secondary interventions. Barb separa-
tion occurred in 18 patients (single-barb separation in 16
cases and multiple-barb separation in two cases), and most
of these patients (12 of 18) did not have device migration,
type I or III endoleak related to the affected device
component, or the need for secondary intervention. Six
patients experienced caudal migration of the proximal
component from which a single barb separation occurred.
Barb separation was observed before migration in two pa-
tients, after migration in two patients, and at the same time
point as migration in two patients. Of note, all these six
patients had an inverted funnel-shaped proximal neck as
well as insufﬁcient device oversizing on the proximal end,
conditions likely contributing to suboptimal apposition of
the sealing stent to the aortic wall. Under these conditions,
some barbs may not have fully engaged into the aortic wall
or may have been subjected to disproportional force.
Secondary interventions. Secondary interventions
occurred at similar rates between the endovascular and
open surgical control patient groups during follow-up
through 5 years, as shown in Fig 5 (log-rank, P ¼ .49).
The Kaplan-Meier estimate of freedom from secondary
intervention was 91.5% for the endovascular patients and
88.4% for the open surgical control patients at 5 years.
Eleven patients in the endovascular group underwent 14
secondary interventions (three patients underwent two
Table II. Deaths included in the thoracic aortic aneurysm (TAA)-related mortality analysis
Cause of death as reported by site CEC adjudication
Endovascular
#30 days 1 Cardiac arrest TAA related
1 Multisystem organ failure TAA related
1 Adult failure to thrive, cerebrovascular disease TAA related
31-365 days 1 Sepsis and respiratory failure TAA related
2 Multisystem organ failure TAA related
1 Respiratory failure TAA related
1 Cardiopulmonary arrest due to pneumonia TAA related
1 Coronary artery disease Indeterminate
1-2 years 1 Respiratory distress TAA related (secondary intervention)a
1 Unknownb Indeterminate
2-3 years 1 Unknownb Indeterminate
3-4 years 2 Unknownb Indeterminate
4-5 years 1 Unknownb Indeterminate
Surgical
#30 days 1 Myocardial infarction TAA related
1 Prolonged cerebral hypoperfusion TAA related
1 Respiratory failure and sepsis TAA related
1 Respiratory failure related to paralysis TAA related
31-365 days 1 Respiratory failure and paraplegia TAA related
1 Cardiopulmonary arrest, aortoesophageal ﬁstula, TAA TAA related
1 Unknownb,c TAA related
1 Respiratory failure, cardiac arrest, aspiration, pneumonia TAA related
1-2 years None
2-3 years None
3-4 years 1 Unknownd Indeterminate
4-5 years 1 Cardiac arrest Indeterminate
1 Shock (possible leaking/rupture of aneurysm) Indeterminate
CEC, Clinical events committee.
aThis patient died within 30 days after the latter of two secondary interventions for continued increase in aneurysm size without detectable endoleak.
bDeath notiﬁcation by Social Security Death Index for these six patients.
cIn this patient, a chain of events beginning within 30 days (including tracheoinnominate ﬁstula requiring surgical intervention, pleural effusion, pericardial
effusion, and multiple infections) led to prolonged hospitalization and may have contributed to the eventual death.
dThe patient died during sleep without recent health issues and the death notiﬁcation was provided by the patient’s family.
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placement of additional stent grafts for the treatment of
proximal or distal type I endoleak (n ¼ 6), component
separation with or without associated type III endoleak
(n ¼ 3), device migration (n ¼ 1), aneurysm growth (n ¼
2), and pseudoaneurysm (n ¼ 1). In addition, one patient
underwent angiography for assessment of endoleak (with
no endoleak detected), and one patient underwent a
femoral-femoral bypass for a right iliac artery occlusion.
Most of the reinterventions (11 of 14) occurred within the
ﬁrst 2 years after the initial endovascular repair. Six patients
in the surgical group underwent secondary interventions.
These reinterventions included treatment of bleeding
complications in four patients, one stent graft placement
for aortoesophageal ﬁstula, and one subsequent thor-
acoabdominal aortic aneurysm. Details of the secondary
interventions are summarized in Table V.
DISCUSSION
This and other trials have demonstrated that TEVAR
with the TX2 has striking early beneﬁts with reduced com-
plications and faster recovery.1 Five-year radiographic
follow-up captures endoleak, migration, aneurysm sac
growth, and device integrity issues with TEVAR, yetreintervention rates are similar in both groups, and the
early beneﬁts are not attenuated by late complications.
Late survival and aneurysm-related survival are not statisti-
cally different between endovascular and open repair.
However, the current study shows a trend with half as
much aneurysm-related mortality with TEVAR (6% vs
12% with open repair), which is consistent with the ﬁnd-
ings of another prior multicenter controlled trial of
TEVAR and open repair that demonstrated similar 5-
year all-cause mortality and improved aneurysm-related
survival with TEVAR.4
Despite reduction of aneurysm-related mortality with
TEVAR, these patients often have severe comorbid dis-
eases, and death due to these comorbid diseases is frequent.
In this unadjusted analysis, 5-year survival rates from all-
cause mortality were 63% in both groups, similar to the
68% with TEVAR and 67% with open repair reported in
the literature.4 This implies that TEVAR should not alter
the indication thresholds used to treat aneurysms or large
ulcers.
This trial was designed with a prespeciﬁed list of severe
complications that experienced clinicians have traditionally
used to measure progress in treatment of thoracic aortic
disease. This was thought to be essential to avoid
Fig 4. Kaplan-Meier estimate of freedom from severe morbid events for the endovascular treatment group and control
group (log-rank, P < .001). The vertical lines represent 95% conﬁdence intervals. Thoracic endovascular aortic repair
(TEVAR) patients have fewer major complications. SE, Standard error.
Table III. Percentage of patients with endoleaks at each follow-up time point based on core laboratory analysis
Time points,a % (No.)
Predischarge 1-month 6-month 1-year 2-year 3-year 4-year 5-year
Patients available (n ¼ 135) (n ¼ 126) (n ¼ 114) (n ¼ 105) (n ¼ 90) (n ¼ 83) (n ¼ 60) (n ¼ 53)
Proximal type I 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1.7 (1) 3.8 (2)
Distal type I 0.7 (1) 0.8 (1) 0.9 (1) 0 (0) 1.1 (1) 1.2 (1) 1.7 (1) 1.9 (1)
Type IIa 1.5 (2) 0.8 (1) 0 (0) 0 (0) 0 (0) 0 (0) 1.7 (1) 0 (0)
Type IIb 7.4 (10) 3.2 (4) 2.6 (3) 1.9 (2) 1.1 (1) 0 (0) 0 (0) 0 (0)
Type III 1.5 (2) 0.8 (1) 0 (0) 1.0 (1) 0 (0) 0 (0) 1.7 (1) 0 (0)
Type IV 1.5 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Unknown 2.2 (3) 0 (0) 0 (0) 1.0 (1) 0 (0) 1.2 (1) 1.7 (1) 0 (0)
Any 14.8 (20) 5.6 (7) 3.5 (4) 3.8 (4) 2.2 (2) 2.4 (2) 8.3 (5) 5.7 (3)
Multiple 0.7 (1) 0.8 (1) 0.9 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
aIn some patients, the same endoleak was detected at multiple time points.
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unimportant reductions of minor complications. For
example, a composite measure might show reduction of
postoperative ileus, anemia, or other minor laboratory ab-
normalities but miss important differences in severe com-
plications. In regard to this predeﬁned severe morbidity
index at 5 years, open repair patients are about twice as
likely to suffer a severe complication compared with
TEVAR patients. Further, if the patient is affected by at
least one severe complication, the average number ofcomplications is three with open repair compared with
two with TEVAR.
In the analysis of all morbid complications, cardiovas-
cular, pulmonary, and vascular complications were reduced
with TEVAR. Gastrointestinal, renal, wound, and neuro-
logic morbidity were similar, although stroke and para-
plegia were both less frequent with TEVAR compared
with open repair. The reductions in severe complications,
stroke, and paraplegia are substantial advantages of
TEVAR that lead to improved clinical utility. This trial
Table IV. Number of patients with increase, decrease, or no change in aneurysm or ulcer size at each follow-up time
point based on core laboratory analysis
Time points,a % (No.)
1-month 6-month 1-year 2-year 3-year 4-year 5-year
Patients available (n ¼ 121) (n ¼ 117) (n ¼ 114) (n ¼ 90) (n ¼ 83) (n ¼ 65) (n ¼ 51)
Decrease 5.8 (7) 32.5 (38) 47.4 (54) 52.2 (47) 59.0 (49) 61.5 (40) 62.7 (32)
No change 93.4 (113) 64.1 (75) 45.6 (52) 44.4 (40) 36.1 (30) 33.8 (22) 31.4 (16)
Increase 0.8 (1) 3.4 (4) 7.0 (8) 3.3 (3) 4.8 (4) 4.6 (3) 5.9 (3)
aIn some patients, an increase in aneurysm or ulcer size was detected at multiple time points.
Fig 5. Kaplan-Meier estimate of freedom from secondary interventions for the endovascular treatment group and open
surgical control group (log-rank, P ¼ .49). The vertical lines represent 95% conﬁdence intervals. TEVAR, Thoracic
endovascular aortic repair; SE, standard error.
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more frequent discharge to home with TEVAR.1-7
It is interesting that there was one late paraparesis after
the ﬁrst year with good recovery, and this occurred in the
TEVAR group. It is speculative that a subgroup of patients
who avoid paraplegia with TEVAR will continue to be at
risk for late spinal cord ischemia because of relative subclin-
ical collateral reduction.
Radiographic follow-up was mandatory in the TEVAR
arm of this trial. Several radiologic events were identiﬁed by
the core laboratory in the TEVAR group and include endo-
leaks, aneurysm sac enlargement, device migration, and de-
vice integrity events. The majority of these ﬁndings are notnoted by sites and do not lead to clinical sequelae or rein-
tervention. Subclinical migration is not uncommon after
TEVAR and has been previously reported with this device
and others.10,11 Detailed imaging analysis of many of
the endoleak and migration cases reveals that the device
had been deployed in a neck location that is not ideal or
properly sized. This emphasizes orthogonal preprocedure
imaging, careful patient and device selection, and deploy-
ment at the intended neck location. This is facilitated
with modern image postprocessing systems, greater physi-
cian experience, and improved delivery systems, previously
described, that were not available at the time of this trial
enrollment.
Table V. Secondary interventions occurring within 5 years
Patient Days Reason for intervention Type of intervention Outcome of reintervention
Endovascular
1 2 Proximal type I endoleaka Stent graft placement Endoleak resolved
2 3 Evaluation of endoleak Angiogram No endoleak detected
3 3 Distal type I endoleaka Stent graft placement;
molding balloon angioplasty
Endoleak resolved
1545 Component separation,
type III endoleak
Stent graft placement Successful bridge of components
4 42 Pseudoaneurysm of thoracic
aorta
Stent graft placement Pseudoaneurysm excluded;
patient died within
30 days of reintervention
5 111 Right iliac artery occlusion Femoral-femoral bypass Improved pulses
6 119 Distal type I endoleak Stent graft placement Endoleak resolved
290 Distal type I endoleak Stent graft placement;
coil embolization
Endoleak resolved
7 361 Aneurysm growth Stent graft placement Aneurysm stable after procedure
697 Persistent aneurysm growth Stent graft placement Components placed successfully;
patient died within 30 days
of reintervention
8 575 Component separation,b type III
endoleak,a and symptoms
Stent graft placement Endoleak resolved
9 650 Component separationb Stent graft placement Lumen widely patent
10 1125 Distal type I endoleak Stent graft placement Endoleak resolved
11 1581 Device migration Stent graft placement Components placed successfully
Surgical
1 1 Bleeding and tamponade Intercostal vessel ligation Bleeding resolved
2 2 Persistent bloody drainage
from chest tubes
Exploratory thoracotomy and
evacuation of intrapleural
hematoma
No signiﬁcant bleeding sources
discovered
3 6 Bleeding into left pleural cavity Reexploration and reseal Bleeding resolved
4 71 Tracheal stoma bleeding Emergent sternotomy and
patch repair of
tracheoinnominate ﬁstula
Bleeding resolved
5 92 Aortoesophageal ﬁstula Stent graft placement Bleeding unresolved; patient
died within 30 days of
reintervention
6 1157 Extensive thoracoabdominal
aortic aneurysm
Hybrid repair with branch vessel
reconstruction followed by
stent graft placement
Aneurysm excluded; no
endoleak detected
aThese endoleaks were not reported by core laboratory analysis of regular follow-up imaging. They were reported by the investigative sites at the time of
secondary interventions (two occurred shortly after the index procedure and one occurred between follow-up visits).
bThese two cases of component separation were reported by the investigative sites at the time of secondary interventions that occurred between follow-up
visits. The core laboratory analysis of follow-up imaging noted decreased device overlap but did not report component separation.
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its becoming the treatment of choice for anatomically suit-
able patients with TAAs and large ulcers. Randomized
controlled studies of endovascular vs surgical repair of
abdominal aortic aneurysms have suggested that higher
rates of secondary interventions erased early beneﬁts after
endovascular repair during long-term follow-up.12-14 In
contrast, this study has shown that although late complica-
tions and reinterventions occur with TEVAR, they occur at
rates similar to those of open repair. Reintervention is infre-
quent, and the early beneﬁts of TEVAR persist through
5 years.
Limitations of this trial include the smaller number of
patients available for follow-up at 5 years, especially in
the surgical group. Standard techniques to improve
research compliance like the Social Security Death Index
were used, but follow-up may have been hampered in
some patients who travel signiﬁcant distances to receivetheir care in units that are specialized in thoracic aortic dis-
eases. Another limitation is the nonrandomized design,
which resulted in imbalance of anatomic, clinical, and un-
known characteristics.
CONCLUSIONS
This trial evaluated 5-year follow-up of patients after
TEVAR and open repair and found similar all-cause mor-
tality and aneurysm-related survival with TEVAR
compared with open repair. There were no ruptures of
the treated aneurysm in either group and no conversions
of TEVAR to open repair. There is a persistent reduction
in severe and major complications with TEVAR compared
with open repair. Endoleak, migration, and aneurysm
growth are observed in routine radiographic follow-up af-
ter TEVAR, yet reintervention rates are similar in both
groups. Taken together, when repair is indicated, TEVAR
is the preferred treatment option for patients with
JOURNAL OF VASCULAR SURGERY
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penetrating ulcers.
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